TY - JOUR
T1 - Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine
T2 - Retrospective analysis of a US-based insurance claims database
AU - Hepp, Zsolt
AU - Rosen, Noah L.
AU - Gillard, Patrick G.
AU - Varon, Sepideh F.
AU - Mathew, Nitya
AU - Dodick, David W.
N1 - Publisher Copyright:
© International Headache Society.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Background Migraine, especially chronic migraine (CM), causes substantial disability; however, health care utilization has not been well characterized among patients receiving different migraine prophylactic treatments. Methods Using a large, US-based, health care claims database, headache-related health care utilization was evaluated among adults with CM treated with onabotulinumtoxinA or oral migraine prophylactic medications (OMPMs). Headache-related health care utilization was assessed at six, nine, and 12 months pre- and post-treatment. The primary endpoint was the difference between pre- and post-index headache-related health care utilization. A logistic regression model was created to test the difference between onabotulinumtoxinA and OMPM-treated groups for headache-related emergency department (ED) visits and hospitalizations. Results Baseline characteristics were comparable between groups. The proportion of patients with ED visits or hospitalizations for a headache-related event decreased after starting onabotulinumtoxinA, but increased after starting an OMPM, for all three cohorts. Regression analyses showed that the odds of having a headache-related ED visit were 21%, 20%, and 19% lower and hospitalization were 47%, 48%, and 56% lower for the onabotulinumtoxinA group compared to the OMPM group for the six-month, nine-month, and 12-month post-index periods, respectively. Conclusions When compared with similar patients who initiated treatment with OMPM, onabotulinumtoxinA was associated with a significantly lower likelihood of headache-related ED visits and hospitalizations.
AB - Background Migraine, especially chronic migraine (CM), causes substantial disability; however, health care utilization has not been well characterized among patients receiving different migraine prophylactic treatments. Methods Using a large, US-based, health care claims database, headache-related health care utilization was evaluated among adults with CM treated with onabotulinumtoxinA or oral migraine prophylactic medications (OMPMs). Headache-related health care utilization was assessed at six, nine, and 12 months pre- and post-treatment. The primary endpoint was the difference between pre- and post-index headache-related health care utilization. A logistic regression model was created to test the difference between onabotulinumtoxinA and OMPM-treated groups for headache-related emergency department (ED) visits and hospitalizations. Results Baseline characteristics were comparable between groups. The proportion of patients with ED visits or hospitalizations for a headache-related event decreased after starting onabotulinumtoxinA, but increased after starting an OMPM, for all three cohorts. Regression analyses showed that the odds of having a headache-related ED visit were 21%, 20%, and 19% lower and hospitalization were 47%, 48%, and 56% lower for the onabotulinumtoxinA group compared to the OMPM group for the six-month, nine-month, and 12-month post-index periods, respectively. Conclusions When compared with similar patients who initiated treatment with OMPM, onabotulinumtoxinA was associated with a significantly lower likelihood of headache-related ED visits and hospitalizations.
KW - Chronic migraine
KW - claims database
KW - emergency department visits
KW - hospitalizations
KW - office visits
KW - onabotulinumtoxinA
KW - out-of-pocket expenses
KW - payer costs
KW - resource utilization
UR - http://www.scopus.com/inward/record.url?scp=84979536983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979536983&partnerID=8YFLogxK
U2 - 10.1177/0333102415621294
DO - 10.1177/0333102415621294
M3 - Article
C2 - 26692400
AN - SCOPUS:84979536983
SN - 0333-1024
VL - 36
SP - 862
EP - 874
JO - Cephalalgia
JF - Cephalalgia
IS - 9
ER -